[Results of ambulatory mono- and combined interferon therapy in advanced kidney tumors].
The authors summarized their experiences during interferon alpha 2b treatment for RCC of advanced stage with special respect to the changes in general condition of patients. Since 1991 ambulantory interferon treatment was carried out on 35 patients. An account is given about the observations on treatment of 31 patients from this a group. After setting up three treatment-groups 4 patients received monotherapy, alpha interferon 2b subcutaneous injection in the first 3 days of the week, in 6-10 mill.i.u.dose. In combination with alpha interferon treatment 7 patients received a daily dose of 500 mg of medroxyprogesteron acetate, while in 20 cases 0.1 mg/body weight vinblastin infusion was given every three weeks with combination of alpha interferon treatment. In four cases complete (CR), in 5 cases partial remission was achieved (PR) while 10 patient remained in an unchanged state (NC). In 12 cases progression can be experienced. Ten patients died during the observation period. The clinical response time was 15 months (3-26), the remission period was in an average 9 months (5-14) and the remission rate (CR + PR) was 29% (31/9). According to the authors, the interferon treatment, despite its significant side effects, can be considered important and remarkable treatment.
Buzogány
I
I
Pécsi Orvostudományi Egyetem, Urológiai Klinika.
Czvalinga
I
I
Götz
F
F
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012074:Remission Induction / Q000379:methods
D007372:Interferons
Ambulanter végzett interferon mono- és kombinációs terápia eredménye elórehaladott vesedaganat esetén.